| Product NDC: | 66302-206 |
| Proprietary Name: | TYVASO |
| Non Proprietary Name: | treprostinil |
| Active Ingredient(s): | 1.74 mg/2.9mL & nbsp; treprostinil |
| Administration Route(s): | ORAL |
| Dosage Form(s): | INHALANT |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 66302-206 |
| Labeler Name: | United Therapeutics Corp. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022387 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20090814 |
| Package NDC: | 66302-206-03 |
| Package Description: | 4 AMPULE in 1 BOX (66302-206-03) > 2.9 mL in 1 AMPULE |
| NDC Code | 66302-206-03 |
| Proprietary Name | TYVASO |
| Package Description | 4 AMPULE in 1 BOX (66302-206-03) > 2.9 mL in 1 AMPULE |
| Product NDC | 66302-206 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | treprostinil |
| Dosage Form Name | INHALANT |
| Route Name | ORAL |
| Start Marketing Date | 20090814 |
| Marketing Category Name | NDA |
| Labeler Name | United Therapeutics Corp. |
| Substance Name | TREPROSTINIL |
| Strength Number | 1.74 |
| Strength Unit | mg/2.9mL |
| Pharmaceutical Classes | Prostacycline Vasodilator [EPC],Prostaglandins I [Chemical/Ingredient],Vasodilation [PE] |